Scholarlink

Trypanosoma brucei and Trypanosoma cruzi are the etiological agent of Human African Trypanosomiasis (sleeping sickness), and American Trypanosomiasis (Chagas disease) respectively. Trypanosomiasis has been the prime concern for global health issues and has been designated as world’s 17th most neglected tropical diseases (NTD) by the World Health Organization (WHO). Trypanosomiasis is the most common among low-income countries and communities and claim immediate addressing to save lacks of lives. However, there are no specific synthetic drugs known to cure the Trypanosomiasis. Existing chemotherapeutics are unable to kill the protozoa and therefore, the causative microorganisms become modified and transformed to more pathogenic forms. Therefore, this issue calls for prime exploration of the disease pathogenesis, and current targets for Trypanosoma brucei and Trypanosoma cruzi for the design and development of potent specific drugs targeting the protozoa.

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Pathogenesis, Mode of Treatment and to Explore Current Targets of Trypanosomiasis

  • 会议论文

  • 发表日期：

    2026年

查看全文
  • Astha Saha,
  • Rukayya,
  • Debapriya Ghosh,
  • Ashaporna Biswas,
  • Sujan Murmu,
  • Amar Faruk Saheb,
  • Tamanna Khatun,
  • Barsha Roy,
  • Asmita Samadder,
  • Sisir Nandi

摘要

Trypanosoma brucei and Trypanosoma cruzi are the etiological agent of Human African Trypanosomiasis (sleeping sickness), and American Trypanosomiasis (Chagas disease) respectively. Trypanosomiasis has been the prime concern for global health issues and has been designated as world’s 17th most neglected tropical diseases (NTD) by the World Health Organization (WHO). Trypanosomiasis is the most common among low-income countries and communities and claim immediate addressing to save lacks of lives. However, there are no specific synthetic drugs known to cure the Trypanosomiasis. Existing chemotherapeutics are unable to kill the protozoa and therefore, the causative microorganisms become modified and transformed to more pathogenic forms. Therefore, this issue calls for prime exploration of the disease pathogenesis, and current targets for Trypanosoma brucei and Trypanosoma cruzi for the design and development of potent specific drugs targeting the protozoa.